insights_auto
为什么 ADAPY 下跌了 3.33%?
深入探索chevron_right
ADAPY:OTCMKTS
Adaptimmune Therapeutics PLC - ADR
US$0.029
arrow_downward
-3.33%(-0.0010) 1 天
10月6日, GMT-4 16:00:00 · USD
search
所有股票代码
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 ADAPY 生成关键数据洞见…
开盘价
US$0.02
最高价
US$0.03
最低价
US$0.02
市值
948.00万
平均成交量
21.00万
成交量
28.20万
52 周最高价
US$0.28
52 周最低价
US$0.00
Beta 版
0.75
流通股数
2.65亿
员工人数
272
开盘价
US$0.02
最高价
US$0.03
最低价
US$0.02
市值
948.00万
平均成交量
21.00万
成交量
28.20万
52 周最高价
US$0.28
52 周最低价
US$0.00
Beta 版
0.75
流通股数
2.65亿
员工人数
272
新闻报道
来自网络来源和新闻合作伙伴
www.tmgm.com
·
19小时前
由于市场对美联储加息预期缓和，道琼斯期货上涨
UA.NEWS
·
13小时前
标普500指数和纳斯达克指数收于历史新高—— 阿纳多卢通讯社
资料
Adaptimmune is a biopharmaceutical company that develops T cell therapies against cancer. The company was founded in 2008 in the UK with links to both Oxford University and the University of Pennsylvania. It has headquarters in Philadelphia and Milton Park.
In August 2024, the US Food and Drug Administration granted accelerated approval to Adaptimmune's Tecelra, a therapy against a rare form of cancer. Tecelra is the first T cell therapy to be approved for use against a solid tumor. In January 2025, the FDA granted breakthrough therapy designation to Adaptimmune's Letetresgene Autoleucel for Treatment of Myxoid/Round Cell Liposarcoma.
In July 2025, Adaptimmune announced their entry into a Definitive Agreement for Sale of Tecelra, lete-cel, and the pre-clinical uza-cel to US WorldMeds for $55M. Wikipedia
Adaptimmune Therapeutics PLC - ADR简介